ß-Cyclodextrin/chitosan-based (polyvinyl alcohol-co-acrylic acid) interpenetrating hydrogels for oral drug delivery.

Gallic acid is an important phenolic compound with extensive applications in the food and pharmaceutical industries due to its health-promoting properties. However, due to its poor solubility and bioavailability, it is rapidly excreted from the body. Therefore, ß-cyclodextrin/chitosan-based (polyvinyl alcohol-co-acrylic acid) interpenetrating controlled release hydrogels were developed to improve its dissolution and bioavailability. pH, polymer ratios, dynamic and equilibrium swelling, porosity, sol-gel, FTIR, XRD, TGA, DSC, SEM and structural parameters like an average molecular weight between crosslinks, solvent interaction parameters, and diffusion coefficient affecting release behavior were investigated. The highest swelling and release were observed at pH 7.4. Furthermore, hydrogels showed good antioxidant and antibacterial properties. Hydrogels improved the bioavailability of gallic acid in a pharmacokinetics study in rabbits. In vitro biodegradation showed that hydrogels were more stable in blank PBS than lysozyme and collagenase. Hydrogels were safe for rabbits (3500 mg/kg) without causing hematological or histopathological changes. The hydrogels showed good biocompatibility, and no adverse reactions were observed. Moreover, the developed hydrogels can be used to improve the bioavailability of various other drugs.

Development of a knowledge, attitude, and practice scale for cardiac rehabilitation for parents of children with heart disease.

PURPOSE: We aimed to (i) develop a Cardiac Rehabilitation Knowledge, Attitude, and Practice Scale for parents of children with heart disease and (ii) test its reliability and validity. METHODS: Based on the theory of knowledge, attitude, and practice, an item pool was constructed through literature review, and 200 parents of children with heart disease were surveyed to test the reliability and validity of the scale. RESULTS: The finalized Knowledge, Attitude, and Practice Scale contains three parts, i.e., knowledge, attitude, and practice, with a total of 34 items. The Cronbach alpha coefficient of the total scale was 0.731, the split-half reliability was 0.730, the content validity was 0.956, and the content validity of each item was 0.917-1. CONCLUSION: The Knowledge, Attitude, and Practice Scale of Cardiac Rehabilitation for Parents of Children with Heart Disease has good reliability and validity, and it can be used as a tool to evaluate the knowledge, attitudes, and practices of parents of children with heart disease participating in cardiac rehabilitation. PRACTICE IMPLICATIONS: The development of the Cardiac Rehabilitation Knowledge, Attitude, and Practice Scale for parents of children with heart disease is of great significance for carrying out targeted education programs in the future to improve the compliance of children with heart disease with cardiac rehabilitation programs.

The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome.

Mutations in the plasminogen activator inhibitor-1 (PAI-1) gene, along with increased PAI-1 levels, have been implicated in the pathogenesis of polycystic ovarian syndrome (PCOS). We investigated a possible influence of the promoter polymorphism (-844 A/G and -675 4G/5G) in the PAI-1 gene on plasma PAI-1 levels in 126 PCOS patients and 97 healthy controls. Levels of total testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), fasting plasma glucose (FPG), fasting insulin, and PAI-1 were measured, and body mass index (BMI), waist-to-hip ratio (WHR), LH/FSH ratio, and homeostasis model assessment for insulin resistance (HOMA-IR) were calculated. PAI-1 -675 4G/5G and -844 A/G gene polymorphisms were also performed. Total testosterone, fasting insulin, and PAI-1 levels; BMI, LH/FSH, and HOMA-IR were significantly higher in PCOS patients than controls (P < 0.05). The odds ratio of 4G/4G genotype, 4G allele, and the combination genotype of 4G/4G and -844 A/A were 2.49 (95% confidence interval (CI), 1.4-4.44), 2.1 (95% CI, 1.43-3.08), and 2.9 (95% CI, 1.41-5.98), respectively, (P < 0.001). In the PCOS group, the PAI-1 level of the A/A was significantly higher than that of the A/G or G/G genotype, similarly was 4G/4G genotype compared with 4G/5G or 5G/5G genotype. The plasma PAI-1 levels of the combination of the PAI-1 -844 A/A and -675 4G/4G or 4G/5G genotypes, or the coadunation of 4G/4G and -844 non-G/G (A/A + A/G) genotypes were significantly high in PCOS women compared with controls. A trend to a positive interaction between PAI-1 -675 4G/5G and -844 A/G gene polymorphism may elevate plasma PAI-1 levels and hypofibrinolysis, which is probably an important hereditary risk factor in PCOS.